Ad hoc: Evotec SE – Bayer discontinues clinical development candidate eliapixant (BAY1817080); Evotec regains the rights to all P2X3 assets

  • Evotec SE announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter—bayer-discontinues-clinical-development-candidate-eliapixant-bay1817080-evotec-regains-the-rights-to-all-p2x3-assets-6141

    Du magst vielleicht auch